June 13, 2022 -- Specifica and Sanofi have reached an agreement under which Specifica’s Generation 3 Antibody Discovery Platform will be transferred enabling the integration into Sanofi’s antibody discovery programs.
Specifica's Gen 3 discovery platform yields a broad diversity of specific and developable antibodies with very high affinities, thereby avoiding downstream hit-to-lead optimization bottlenecks such as affinity maturation and developability optimization, according to the company.
The Gen 3 libraries combine clinically validated antibody frameworks with compatible binding loop sequences from natural human antibodies that have been purged of sequence-based developability liabilities.
Specifica CEO Ken Sharples in a statement said the partnership with Sanofi will provide a "complete antibody discovery platform through a combination of Gen 3 libraries, antibody optimization solutions, and integrated discovery tools."
Copyright © 2022 scienceboard.net